The settlement agreement will extend market exclusivity for AbbVie's JAK inhibitor in the U.S. until 2037—providing pediatric ...

President Donald Trump is considering tariff exemptions for certain “non-patented” pharmaceuticals, though the White House ...

LB Pharma has finally done it. The biotech IPO stalemate has been broken, with the neuroscience-focused company landing on ...

Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval ...

Capsida has yet to disclose the exact cause of death. The patient had received the gene therapy CAP-002 for a type of ...

A draft executive order obtained by The New York Times purports to clamp down on the pharmaceutical industry's ability to buy ...

Analysts at BMO Capital Markets expect the lack of other exon-44-skiping therapies to facilitate a "smooth" approval process ...

Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech ...

Claiming that the domestic market undervalues pharma innovation, Merck has decided to pull the plug on all of its R&D efforts ...

Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

New York City has seen increased life sciences employment during the past decade as public funding and key projects like ...

While a win for consumers, the regulatory action did nothing to stem the manufacture of compounded versions of the popular ...